Smart scan strategy aims to customize lymphoma therapy

NCT ID NCT06050694

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026 · Last updated May 13, 2026 · Updated 4 times

Summary

This study tests a new way to treat diffuse large B-cell lymphoma (DLBCL) by using early PET scans and blood tests (ctDNA) to decide the best treatment plan. About 40 adults with untreated DLBCL will receive standard chemo plus the drug glofitamab, but the number of cycles and additional treatments depend on how well the cancer responds early on. The goal is to give less chemo to low-risk patients and a stronger, targeted approach to high-risk patients, improving effectiveness while reducing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••
Princess Margaret Cancer Centre
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)